Company Overview and News
Boston Scientific Corporation (BSX - Free Report) has been gaining investor confidence on consistently encouraging results. Over the past six months, the company’s share price has outperformed its industry. The stock has gained 27.1% compared with the industry’s 19% rally. Also, the company has outperformed the S&P 500’s 8.7% rise.
MASI BSX AMED ISRG
Sahajanand Medical Technologies, or SMT, the Surat-based maker of cardiac stents isn’t content with what it has achieved in India. The management now wants to take the battle to foreign shores.
ABT YESBANK 532648 YYBKY ABT BSX MS
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Boston Scientific (BSX - Free Report) , which belongs to the Zacks Medical - Products industry, could be a great candidate to consider.
Over the last six months, Boston Scientific (NYSE:BSX) has experienced an incredible rally. BSX stock has moved higher in 24 of the past 28 weeks, a streak that started back in March.
On Oct 1, we issued an updated research report on Boston Scientific Corporation (BSX - Free Report) . The company’s recent acquisitions have added various new products (though many are under development) with immense potential to its portfolio. The stock carries a Zacks Rank #2 (Buy).
MASI BSX AMED ISRG
Baxter International Inc. (BAX - Free Report) recently announced collaboration with the University of Southern California Center for Body Computing (“USC CBC”) to develop innovative digital solutions designed to help save and sustain lives. With the development, Baxter aims to integrate digital capabilities to advance care.
BSX SYK NR BAX MDT
2018-10-02 247wallst - 2
Stocks were taking a breather on Tuesday, but that is after the Canada trade deal sent the Dow Jones industrials up about 190 points and the S&P 500 up over 10 points. While the U.S. indexes are effectively at all-time highs, many investors have seen lower upside from buying on market pullbacks than in prior years. Now the investing community has to consider how to position their investments for the rest of 2018 and into 2019.
GE SQ GEC SQNXF SKX SEAS BSX TSLA TRI GNE MS ECL ETSY
U.S. equities are moving powerfully higher on Monday, with the major large-cap indices testing recent record highs, after the United States reached a new trade deal with Mexico and Canada. Effectively “NAFTA 2.0”, the deal, which carries the moniker USMCA, will solve deficiencies in the original NAFTA deal and open new markets for U.S. farmers and manufacturers … at least according to President Trump.
UAL HON BSX CAT CSCO MSFT BA DHR
On Wednesday the bulls were largely in charge leading up to and even after the Federal Reserve ratcheted up interest rates by the expected quarter of a point. With a little time to think about it though, before the closing bell rang, doubt dragged the S&P 500 to a loss of 0.33%. The Nasdaq followed suit, closing down 0.21%.
GPRO ZION WU NDAQ BSX AMD
Boston Scientific Corporation (BSX - Free Report) recently launched its new urology device globally. Called LithoVue Empower Retrieval Deployment Device, it will be used together with the LithoVue Single-Use Digital Flexible Ureteroscope and a compatible nitinol retrieval basket. This latest development remains in line with Boston Scientific’s strategy to address inefficiencies during stone procedures.
MASI BSX VEEV ATHN
Boston Scientific Corporation’s (BSX - Free Report) recent receipt of Premarket Approval (PMA) to market the Eluvia Drug-Eluting Vascular Stent System expanded its Peripheral Interventions (PI) suite. Notably, the company received CE Mark for the stent system in 2016.
MASI BSX AMED ISRG
Expectations were low for the COAPT trial due to disappointing results from French-funded study MITRA-FR. However, some analysts still believed COAPT was different enough to see a more positive outcome.
ABT BSX ABT EW
REUTERS: The U.S. Food and Drug Administration on Monday approved Boston Scientific Corp's drug-coated stent Eluvia to treat narrowed arteries in the leg.
(Reuters) - The U.S. Food and Drug Administration on Monday approved Boston Scientific Corp’s drug-coated stent Eluvia to treat narrowed arteries in the leg.
An upbeat economic scenario and strong growth in corporate earnings have encouraged investors to load up on U.S. stocks. The Dow Jones Industrial Average’s rise to an all-time high reflects the bullishness.
MASI QDEL BSX WBA ISRG UTX CVS MDT EOG
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to BSX / Boston Scientific Corp. on message board site Silicon Investor.
as of ET